Overview

Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma

Status:
NOT_YET_RECRUITING

Trial end date:
2032-08-14

Target enrollment:

Participant gender:

Summary

This single-arm, phase 2 trial evaluates the efficacy and safety of de-escalated radiotherapy (restricted to the primary tumor, omitting prophylactic neck irradiation) combined with neoadjuvant and adjuvant toripalimab immunotherapy, and concurrent chemotherapy in patients with nasopharyngeal carcinoma staged N0 or N1, where nodal involvement is strictly confined to the retropharyngeal lymph nodes.

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-sen University

Treatments:

Cisplatin
toripalimab